Alteration of p73 in acute myelogenous leukemia

American Journal of Hematology

Volumn 79, Issue 1, 2005, Pages 1-7

  Sahu, Geeta Ram ^a   Mishra, Rajakishore ^a   Nagpal, Jatin Kumar ^a   Das, Bibhu Ranjan ^a,b,c  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b Clinical Reference Laboratories   (India)

^c Maharashtra Industrial Development Corporation India   (India)

Author keywords

AML; Methylation; Mutation; Over expression; p73

Indexed keywords

MESSENGER RNA; PROTEIN P73;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EXON; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; P73 GENE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UNTRANSLATED REGION; WESTERN BLOTTING;

ADULT; AGED; BASE SEQUENCE; DNA METHYLATION; DNA PRIMERS; DNA-BINDING PROTEINS; EXONS; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 18044381319     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20284     Document Type: Article

References (54)

1. Radich JP, Kopecky KJ, Appelbaum F, Willman CL, Collins SJ. N-ras mutations in adult de novo acute myelogenous leukemia and clinical significance. Blood 1990;76:801-807.
2. Neubauer A, He M, Schmidt CA, Huhn D, Liu ET. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994;83:1603-1611.
3. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 on the N-ras gene in acute myeloid leukemia. Leukemia 1994;8: 1682-1687.
4. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute non-lymphocytic leukemia; a new association. Blood 1983;61:994-998.
5. Rowley JD. Recurring chromosome abnormalities in leukemia and lymphoma. Semin Hematol 1990;27:122-136.
6. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
7. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456.
8. Koeffler HP, Miller C, Nicolson MA, Ranyard J, Bosselman RA. Increased expression of p53 protein in human leukemia cells. Proc Natl Acad Sci USA 1986;83:4035-4039.
9. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 1987;84:7716-7719.
10. Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995;5:84-90.
11. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819.
12. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997;389:191-194.
13. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-1449.
14. Oren M. Lonely no more: p53 finds its kin in a tumor suppressor heaven. Cell 1997;90:829-832.
15. Ross RA, Spengler BA, Domenech C, Porubcin M, Rettig WJ, Biedler JL. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ 1995;6:449-456.
16. Nagai H, Negrini M, Carter SL, et al. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1995;55:1752-1757.
17. Dracopoli NC, Hamett P, Bale SJ, et al. Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 1989;86:4614-4618.
18. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976;3:2303-2308.
19. Hayashi K. A simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl 1991;1: 34-38.
20. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998;9:897-903.
21. Mai M, Huang H, Reed C, et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998;51:359-363.
22. Sunahara M, Ichimiya S, Nimura Y, et al. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 1998;13:319-323.
23. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998;58:1380-1383.
24. Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998;58:2076-2077.
25. Cheng J, Haas M, Yeargin J, Friedmann T, Haas M. Frequent mutation in the p53 tumour suppressor gene in human leukemia T-cell line. Mol Cell Biol 1990;10:5502-5509.
26. Stirewalt DL, Clurman B, Appelbaum FR, Willman CL, Radich JP. p73 mutations and expressions in adult de novo acute myelogenous leukemia. Leukemia 1999;13:985-990.
27. Wutz A, Smrzka OW, Schweifer N, Schellander K, Wagner EF, Barlow DP. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 1997;389:745-749.
28. Relk W, Constancia M. Making sense or antisense. Nature 1997;389:669-671.
29. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumour suppressor gene. Oncogene 1992;7:927-933.
30. D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired mutations in small cell lung cancer cell lines and tumours. Oncogene 1992;7:339-346.
31. Zhang W, Hu G, Estey E, Hester J, Deisseroth A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen stimulated normal blood cells. Oncogene 1992;7:1645-1647.
32. Zhang W, Deisseroth AB. Conformational change of p53 protein in growth factor stimulated human myelogenous leukemia cells. Leuk Lymphoma 1994;14:251-255.
33. Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemic virus like DNA sequence. Mol Cell Biol 1984;4:1402-1410.
34. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangement of the cellular p53 gene in erythroleukemia cells transformed by Friend virus. Nature 1985;314:633-636.
35. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-2623.
36. Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94(3):1113-1120.
37. Van Zee KJ, Calvano JE, Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998;16:2723-2727.
38. Wong IH, Ng MH, Lee JC, Lo KW, Chung YF, Huang DP. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. Br J Haematol 1998; 103:168-175.
39. Zion M, Ben-Yehuda D, Avraham A, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1994;91: 10722-10726.
40. Litz CE, Vos JA, Copenhaver CM. Aberrant methylation of the major breakpoint cluster region in chronic myeloid leukemia. Blood 1996;88:2241-2249.
41. Wu H-K, Weksberg R, Minden MD, Squire JA. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. Biochem Biophys Res Commun 1997;231: 466-472.
42. Randhawa GS, Cui H, Barletta JA, et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 1998;91:3144-3147.
43. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-196.
44. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59: 793-797.
45. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain and other human cancers. Cancer Res 1999;59:798-802.
46. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997;13:444-449.
47. Corn PG, Kuerbitz SJ, Van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999;59:3352-3356.
48. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-692.
49. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95:5246-5250.
50. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-3157.
51. Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997;90:4078-4091.
52. Peters UR, Tschan MP, Kreuzer KA, et al. Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res 1999;59:4233-4236.
53. Bartolomei MS, Webber AL, Brunkow ME, Tilghman SM. Epigenetic mechanisms underlying the imprinting of the mouse H19 gene. Genes Dev 1993;7:1663-1673.
54. Schwab M, Praml C, Amler LC. Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 1996;16:211-229.